Relationship between immune-related adverse events and treatment effectiveness in extensive disease small cell lung cancer.

ABSTRACT:

Background

This study aimed to assess the relationship between immune response adverse events (irAEs) and treatment efficacy in patients with extensive disease small cell lung cancer (ED-SCLC).

Methods

We retrospectively evaluated the clinical effects in 40 ED-SCLC patients who had received immune-checkpoint inhibitors (ICIs), platinum agents, and etoposide between September 2019 and September 2021. We identified and compared patients belonging to two groups: irAE and non-irAE.

Results

Fifteen patients experienced irAEs, and 25 did not. The median progression-free survival in patients with irAE was longer than that in patients without irAE (12.6 months [95% CI: 6.3-19.3 months] vs. 7.2 months [95% CI: 5.8-7.9 months], p = 0.0108). However, the median overall survival

SUBMITTER: Yokoo K 

PROVIDER: S-EPMC10423651 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature